Blocking C-MET and BRAF pathways in melanoma to overcome resistance in mouse models
The importance of the Phase III JAVELIN LUNG 100 trial in non-small-cell lung cancer
What to do with BRAF-mutant melanoma patients who have a poor prognosis?
Understanding resistance to combined BRAF and MEK inhibiton in melanoma and the significance of CDK4
Functional imaging for influencing management: paradigm shift or pipe dream?